Rigel CEO awarded 31,700 performance stock options
Rigel Pharmaceuticals CEO Raul R. Rodriguez reported a performance-based stock option grant that became fully vested on June 17, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Rigel Pharmaceuticals CEO Raul R. Rodriguez reported a performance-based stock option grant that became fully vested on June 17, 2026. The award covers 31,700 shares of common stock under an employee stock option, with an exercise price of $22.49 per share and an expiration date of January 29, 2035. The filing shows this as a compensation-related acquisition, not an open-market buy or sale, and lists 31,700 derivative shares held following the transaction.
Insider Trade Summary
Grant/Award: 31,700 shares
Grant/Award
1 txn
Insider
RODRIGUEZ RAUL R
Role
CEO, President
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Employee Stock Option (right to buy) | 31,700 | $0.00 | $0.00 |
Holdings After Transaction:
Employee Stock Option (right to buy) — 31,700 contracts (Direct)
Footnotes (2)
- F1. The Reporting Person was granted a stock option with a performance-based condition with respect to 31,700 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met.
- F2. The option was fully vested on June 17, 2026, the date the determination was made that the performance metric had been met.
Key Figures
Option shares granted: 31,700 shares
Exercise price: $22.49 per share
Total derivative shares after transaction: 31,700 shares
+3 more
6 metrics
Option shares granted
31,700 shares
Employee stock option with performance-based condition
Exercise price
$22.49 per share
Closing price on Nasdaq on January 29, 2025
Total derivative shares after transaction
31,700 shares
Options held following June 17, 2026 vesting determination
Vesting date
June 17, 2026
Date performance metric was determined to be met; option fully vested
Expiration date
January 29, 2035
Option expiration for the 31,700-share grant
Transaction code
A
Grant, award, or other acquisition of derivative security
Key Terms
performance-based condition, Section 16, exercise price, vested
4 terms
performance-based condition financial
"The Reporting Person was granted a stock option with a performance-based condition with respect to 31,700 shares"
Section 16 regulatory
"In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied"
Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.
exercise price financial
"The exercise price of this option is $22.49, which is the closing price"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vested financial
"The option was fully vested on June 17, 2026, the date the determination was made"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Rigel Pharmaceuticals (RIGL) report for its CEO?
Rigel Pharmaceuticals reported that CEO Raul R. Rodriguez acquired an employee stock option covering 31,700 shares of common stock. This was a compensation grant that became reportable once a performance metric was determined to be met on June 17, 2026.
What is the exercise price of the Rigel (RIGL) CEO’s performance-based option?
The exercise price of the CEO’s performance-based stock option is $22.49 per share. According to the disclosure, this price equals the closing price of Rigel’s common stock on Nasdaq on the original grant date of January 29, 2025.
When did the performance condition for the Rigel (RIGL) CEO’s option get satisfied?
The performance condition for the CEO’s stock option was determined to be satisfied on June 17, 2026. On that date, the option became fully vested, triggering the requirement to report the award under Section 16 as shown in the filing.
When does the Rigel (RIGL) CEO’s newly vested option expire?
The CEO’s performance-based stock option expires on January 29, 2035. This gives a long exercise window following full vesting on June 17, 2026, during which the option can be exercised at the fixed $22.49 per share exercise price.
Is the Rigel (RIGL) CEO’s Form 4 transaction an open-market buy or sale?
The reported transaction is not an open-market buy or sale. It is a compensation-related grant of an employee stock option that became reportable once its performance-based vesting condition was met, resulting in 31,700 vested derivative shares held by the CEO.
AI-generated analysis. How Rhea-AI works. Not financial advice.
